Michele Aieta

Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis

Giuseppe Di Lorenzo, Riccardo Autorino, Gianni Bruni et al. · Annals of Oncology · 2009 · 205 citations · Full text

Medicine, Oncology, Pharmacology +17

Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone

Cristian Lolli, Orazio Caffo, Emanuela Scarpi et al. · Frontiers in Pharmacology · 2016 · 203 citations · Full text

Medicine, Oncology, Pharmacology +15

Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study

Alessandro Russo, Marco Russano, Tindara Franchina et al. · Advances in Therapy · 2020 · 168 citations

Medicine, Immunology, Oncology +17

Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial

Vanesa Gregorc, Silvia Novello, Chiara Lazzari et al. · The Lancet Oncology · 2014 · 158 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study

PierFranco Conte, Antonio Frassoldati, Giancarlo Bisagni et al. · Annals of Oncology · 2018 · 155 citations · Full text

Medicine, Oncology, Pharmacotherapy +17